153 related articles for article (PubMed ID: 22532226)
1. The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.
Longuespée R; Boyon C; Castellier C; Jacquet A; Desmons A; Kerdraon O; Vinatier D; Fournier I; Day R; Salzet M
Histochem Cell Biol; 2012 Jul; 138(1):141-54. PubMed ID: 22532226
[TBL] [Abstract][Full Text] [Related]
2. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.
Lemaire R; Menguellet SA; Stauber J; Marchaudon V; Lucot JP; Collinet P; Farine MO; Vinatier D; Day R; Ducoroy P; Salzet M; Fournier I
J Proteome Res; 2007 Nov; 6(11):4127-34. PubMed ID: 17939699
[TBL] [Abstract][Full Text] [Related]
3. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract][Full Text] [Related]
4. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
[TBL] [Abstract][Full Text] [Related]
5. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
7. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
8. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
[TBL] [Abstract][Full Text] [Related]
9. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
10. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation.
Armes JE; Davies CM; Wallace S; Taheri T; Perrin LC; Autelitano DJ
Pathology; 2013 Jan; 45(1):49-54. PubMed ID: 23222243
[TBL] [Abstract][Full Text] [Related]
11. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer.
Kim SC; Kim MK; Kim YH; Ahn SA; Kim KH; Kim K; Kim WK; Lee JH; Cho JY; Yoo BC
Oncol Lett; 2014 Aug; 8(2):566-574. PubMed ID: 25013471
[TBL] [Abstract][Full Text] [Related]
12. MALDI Mass Spectrometry Imaging of Early- and Late-Stage Serous Ovarian Cancer Tissue Reveals Stage-Specific N-Glycans.
Briggs MT; Condina MR; Ho YY; Everest-Dass AV; Mittal P; Kaur G; Oehler MK; Packer NH; Hoffmann P
Proteomics; 2019 Nov; 19(21-22):e1800482. PubMed ID: 31364262
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
14. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
[TBL] [Abstract][Full Text] [Related]
15. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Köbel M; Kalloger SE; Boyd N; McKinney S; Mehl E; Palmer C; Leung S; Bowen NJ; Ionescu DN; Rajput A; Prentice LM; Miller D; Santos J; Swenerton K; Gilks CB; Huntsman D
PLoS Med; 2008 Dec; 5(12):e232. PubMed ID: 19053170
[TBL] [Abstract][Full Text] [Related]
18. Low-mass-ion discriminant equation (LOME) for ovarian cancer screening.
Lee JH; Yoo BC; Kim YH; Ahn SA; Yeo SG; Cho JY; Kim KH; Kim SC
BioData Min; 2016; 9():32. PubMed ID: 27752286
[TBL] [Abstract][Full Text] [Related]
19. Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.
Sánchez-Martín D; Martínez-Torrecuadrada J; Teesalu T; Sugahara KN; Alvarez-Cienfuegos A; Ximénez-Embún P; Fernández-Periáñez R; Martín MT; Molina-Privado I; Ruppen-Cañás I; Blanco-Toribio A; Cañamero M; Cuesta AM; Compte M; Kremer L; Bellas C; Alonso-Camino V; Guijarro-Muñoz I; Sanz L; Ruoslahti E; Alvarez-Vallina L
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13791-6. PubMed ID: 23918357
[TBL] [Abstract][Full Text] [Related]
20. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
